Jun 07, 2023 / 06:00PM GMT
Eun Yang - Jefferies - Analyst
So, next presenting company is Astria. We are going to be having a fire-side chat. But before we begin, Jill, would you like to give us a kind of a quick overview? Then we can go into Q&As.
Jill Milne - Astria Therapeutics, Inc. - Co-Founder & CEO
That sounds great. Thanks, Eun. So, I'll start by saying, during our remarks today, we will make statements related to our business based on current and future expectations that may be considered forward-looking statements under applicable securities laws.
So, with that, I will advance to the next slide. So, at Astria Therapeutics, we are developing therapeutics to treat patients affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of an enzyme called plasma kallikrein. Plasma kallikrein is a clinically and commercially validated target for the treatment of hereditary angioedema, or HAE.
HAE is a severe, rare disease. It is truly a life-changing diagnosis for those people who are affected
Astria Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers